Table of contents

Clinical/translational cancer immunotherapy

• Original research: Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activation and extracellular matrix reorganization in the tumor microenvironment (30 August, 2024)

  Brenda C O'Connell, Charley Hubbard, Nora Zizlsperger, Donna Fitzgerald, Jeffrey L Kutok, Judith Varner, Robert Ilaria, Melody A Cobleigh, Dejan Juric, Kate H R Tkaczuk, Anthony Elias, Arielle Lee, Shaker Dakhil, Erika Hamilton, Hatem Soliman, Stephane Peluso
• Original research: Nivolumab maintenance improves overall survival of patients with advanced melanoma who experience severe immune-related adverse events on nivolumab plus ipilimumab (28 August, 2024)

  Anna K Maloney, Anita Giobbie-Hurder, Nikita Katukota, Miklos C Fogarasi, Patrick A Ott, F Stephen Hodi, Tamara A Sussman, Ann W Silk, Rizwan Haq, David Liu, Megan Insco, Elizabeth I Buchbinder
• Original research: Safety and tolerability of immune checkpoint inhibitors in people with HIV infection and cancer: insights from the national prospective real-world OncoVIHAC ANRS CO24 cohort study (22 August, 2024)

  Lambert Assoumou, Raghiatou Baldé, Christine Katlama, Baptiste Abbar, Pierre Delobel, Thierry Allegre, Armelle Lavole, Alain Makinson, Olivia Zaegel-Faucher, Laurent Greillier, Cathia Soulie, Marianne Veyri, Mathilde Bertheau, Michèle Algarte Genin, Séverine Gibowski, Anne-Geneviève Marcelin, Kevin Bihan, Marine Baron, Dominique Costagliola, Olivier Lambotte, Jean-Philippe Spano
• Original research: An IL-7 fusion protein targeting EDA fibronectin upregulates TCF1 on CD8+ T-cells, preferentially accumulates to neoplastic lesions, and boosts PD-1 blockade (13 August, 2024)

  Cesare Di Nitto, Domenico Ravazza, Ettore Gilardoni, Thomas Look, Miaomiao Sun, Eleonora Prodi, Vlad Moisoiu, Christian Pellegrino, Markus G. Manz, Emanuele Puca, Michael Weller, Tobias Weiss, Dario Neri, Roberto De Luca
• Original research: Epithelium/imcDC2 axis facilitates the resistance of neoadjuvant anti-PD-1 in human NSCLC (12 August, 2024)

  Yongyuan Chen, Zheyu Shao, Zhixing Hao, Zhongwei Xin, Xiaoke Chen, Lijian Huang, Di Chen, Mingjie Lin, Qinyuan Liu, Xia Xu, Jinfan Li, Dang Wu, Jun Yan, Ying Chai, Pin Wu
• Original research: Five-year follow-up of neoadjuvant PD-1 inhibitor (sintilimab) in non-small cell lung cancer (12 August, 2024)

  Bolun Zhou, Fan Zhang, Wei Guo, Shuhang Wang, Ning Li, Bin Qiu, Liang Zhao, Jian Li, Kang Shao, Qi Xue, Fang Lv, Shugeng Gao
• Original research: Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden (6 August, 2024)

  Michael Schenker, Mauricio Burotto, Martin Richardet, Tudor-Eliade Ciuleanu, Anthony Gonçalves, Neeltje Steeghs, Patrick Schoffski, Paolo A Ascierto, Michele Maio, Iwona Lugowska, Lorena Lupinacci, Alexandra Leary, Jean-Pierre Delord, Julieta Grasselli, David S P Tan, Jennifer Friedmann, Jacqueline Vuky, Marina Tschaika, Somasekhar Konduru, Sai Vikram Vemula, Ruta Slepetis, Georgia Kollia, Misena Pacius, Quyen Duong, Ning Huang, Parul Doshi, Jonathan Baden, Massimo Di Nicola
• Original research: Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2) (3 August, 2024)

  Diwakar Davar, Ludimila Cavalcante, Nehal Lakhani, Justin Moser, Michael Millward, Meredith McKean, Mark Voskoboynik, Rachel E Sanborn, Jaspreet S Grewal, Ajita Narayan, Amita Patnaik, Justin F Gainor, Mario Sznol, Amanda Enstrom, Lori Blanchfield, Heidi LeBlanc, Heather Thomas, Michael J Chisamore, Stanford L Peng, Allison Naumovski